AusDiagnostics announces Marco Calzavara as Business Director for UK and Europe
Monday, May 24, 2021
AusDiagnostics is delighted to announce the appointment of Marco Calzavara as its new Business Director for UK and Europe.
In his new role, Mr Calzavara will be responsible for operations and staff across the UK and Europe.
Mr Calzavara is the former founder and president of the esteemed biotechnology company Bioline, now owned by Meridian Bioscience. He established Bioline in 1992 in United Kingdom, growing the business from humble beginnings into a global organisation with subsidiaries throughout United Kingdom, United States, Singapore, Italy, Germany and Australia, each with an impressive network of distributors. Read more
AusDiagnostics opens new state-of-the-art production facility and
launches new extraction kits
Tuesday, September 22, 2020
AusDiagnostics has opened a new state-of-the-art production facility in Sydney, alongside the launch of
their new Puryx™ extraction kit product line.
The Puryx™ product line encompasses kits that extract pathogen derived nucleic acids from patient samples to prepare them for subsequent laboratory detection of infections and other pathogens, including testing for COVID-19.
In response to the global shortage of necessary reagents and kits to adequately address COVID-19
testing, AusDiagnostics partnered with the Federal Government in June to pledge the creation of the new facility to meet the current and future demands. Read more
AusDiagnostics announces Scott Gilroy as new CEO
Monday, August 24, 2020
AusDiagnostics announces the appointment of Scott Gilroy as the company's new CEO.
Mr Gilroy will be taking on the leadership role from Founder and Managing Director Professor Keith Stanley who has led the company for the last 14 years.
Reflecting on his appointment, Mr Gilroy said: “I have always maintained a deep love for science and the way it changes our lives for the better. To have the opportunity to lead a dedicated and inspiring group of people at the heart of responding to the COVID-19 pandemic is truly humbling." Read more
AusDiagnostics releases panel for testing 2019-nCoV
Monday February 3, 2020
AusDiagnostics has developed a panel for typing of coronaviruses that includes the novel coronavirus causing the current outbreak together with SARS, MERS and four more commonly found coronaviruses.
AusDiagnostics releases IVD kit for detection of dermatophytes
Monday, January 21, 2019
AusDiagnostics has CE marked a new kit for detection of dermatophytes. These fungal pathogens cause athlete’s foot, and a number of itchy skin, hair and nail infections. Currently the diagnosis requires culture of the fungi which can take up to 4 weeks. The new kit released by AusDiagnostics will give a result in 4 hours making the selection of treatment much more timely for the patient.
Global health threat of antibiotic resistance can be reduced with
rapid diagnosis and responsible use
Tuesday, November 6, 2018
Minor infections could kill millions of people globally if antibiotic resistance continues to spread at the current rate. AusDiagnostics Managing Director Professor Keith Stanley says that the key to combating the spread of antibiotic resistance is rapid diagnosis, followed by responsible use of antibiotics.
“AusDiagnostics has released a new molecular testing kit for detection of antibiotic resistance in Gram positive bacteria in blood cultures,” he explains.
“This allows hospitals to get advance warning of antibiotic resistant bacteria in a matter of hours without having to wait for bacteria to grow on petri dishes for one to two days.” Read more
AusDiagnostics provides new weapons in war against antibiotic resistance
Wednesday, September 19, 2018
The overuse and misuse of antibiotics has allowed the development of antibiotic-resistant bacteria. In particular, the emergence of carbapenem resistance in bacteria is a major public health concern because these agents are regarded as one of the last effective therapies available for treating serious infections.
Two papers in the Journal of Antimicrobial Chemotherapy illustrate very different approaches to the problem. In one 'Evaluation of the AusDiagnostics MT CRE EU assay for the detection of carbapenemase genes and transferable colistin resistance determinants mcr-1/-2 in MDR Gram-negative bacteria' (Meunier D et al.). a new kit for reference laboratories is validated.
In the second 'Evaluation of multiplex tandem PCR (MT-PCR) assays for the detection of bacterial resistance genes among Enterobacteriaceae in clinical urines'. (Schmidt et al.) the approach is directed more toward the clinician. Instead of asking the question “what resistance genes are present”, this kit asks the question “which antibiotics can I use on this patient” Read more
AusDiagnostics product tests for five STIs including Mycoplasma genitalium
Thursday, July 12, 2018
A relatively unknown STI, which is causing concern among doctors and health professionals around the world, can be tested by AusDiagnostics – Australia’s leading commercial supplier of highly multiplexed diagnostics to microbiology laboratories. Mycoplasma genitalium (MG), which was identified as a bacteria in the 1980s, is spread through unprotected intercourse and is now becoming resistant to antibiotics. Read more
AusDiagnostics achieves ISO accreditation for manufacturing IVDs in London
Wednesday, May 20, 2018
AusDiagnostics - Australia’s leading commercial supplier of highly multiplexed diagnostics to microbiology customers - has received ISO accreditation for manufacturing of its in vitro diagnostic product in London, UK. With 30 products included in the Australian Register of Therapeutic Goods (ARTG) and CE marked, the company offers choice to pathology customers in different regions where the clinical needs can be different Read more